BerGenBio

Pre-Annual General Meeting Information • Apr 7, 2022

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

Bergen, Norway - 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its

Annual General Meeting virtually on 28 April 2022 at 10:00 hours (CEST).

The notice, power of attorney and proposal from Nomination Committee are

attached to this release. The notice will be sent to all registered shareholders

and is available on the Company's website:

https://www.bergenbio.com/investors/general-meetings/

All shareholders are encouraged to exercise their shareholder rights, either

through advance electronically voting through VPS Investor Services, by using

the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the

person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through

the company's website or VPS Investor Service within 25 April 2022 16:00 hours

(CEST). Virtual participants need to be logged in to the meeting before 10:00

hours (CEST) 25 April 2022.

All shareholders will receive a reference number and a pin code required for

registration through the company's website. Reference number and pin code will

be received either by VPS Investor Service or by post depending if the

shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS.

- END -

AboutBerGenBioASA

BerGenBiois a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate,bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broadphase II clinical development programme

focused on combination and single agent therapy in lung cancer, leukaemia and

COVID-19. A first-in-class functional blocking anti-AXL antibody,tilvestamab, is

undergoingphase I clinical testing. In parallel,BerGenBiois developingacompanion

diagnostic test to identify patient populations most likely to benefit

frombemcentinib: this is expected to facilitate more efficient registration

trials supporting a precision medicine-based commercialisation strategy.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company

is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,

visit?www.bergenbio.com

Contacts

Martin Olin, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.